At the heart of a case involving a prescription drug is the question of risks – what risks exist, what risks were known, and what risks were warned about. All of us have seen prescription drug advertisements that include a[...]
New Rules for Clinical Trial Transparency: Did the NIH and FDA Provide a Solution or Merely Identify a Problem?
Clinical trials—or the lack thereof—often play a central role in cases involving dangerous drugs and medical devices. If and when manufacturers had knowledge of the dangers associated with their products goes directly to the liability of those manufacturers. All too[...]
The deaths of Eric Garner and Michael Brown have brought several topics to the forefront of public discussion in recent weeks. Questions of racial profiling, discrimination and the threat of an increasing police state have bubbled up into the public[...]
Last month, the Supreme Court decided not to review a decision involving lay witness opinion testimony. The case – Cuti v. United States, 720 F.3d 453 (2nd Cir. 2013) – may be valuable for anyone who is involved in complex[...]
Getting Outside of the Office: Support the Children’s Research Fund Junior Board at Cocktails for a Cause
In addition to my passion for helping injured plaintiffs through my role as an associate attorney with Wexler Wallace’s mass torts practice, I am passionate about helping to improve the quality of health care delivered to pediatric patients through my[...]
Earlier this year, I wrote about the online storage company Dropbox adding an arbitration clause to its customer service agreement. It seems Dropbox is in very good company on the Internet these days. According to New York Times blog “The[...]